‘Military To Start Testing Service Members For The Psychedelic Psilocin, Memo Shows’ – Marijuana Moment
https://www.marijuanamoment.net/military-to-start-testing-service-members-for-the-psychedelic-psilocin-memo-shows/
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects Of ZBTB46 mRNA With PD1 Immunotherapy In Control Of Tumor Growth In Animal Model
Preprint of results from animal study shows restriction of tumor growth in mice treated with ZBTB46 mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology
Nanoparticle treatment combined with
Republicans Seek Documents, Schedule Hearing Related To FDA’s Response To Baby-Formula Shortage
House Republicans are reportedly speeding up their scrutiny of the FDA and the White House's handling of the baby formula shortage last year.
Despite Failed Phase 3 Study, FDA Staff Says Biogen’s ALS Drug May Have Clinical Benefit
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc’s (NASDAQ:BIIB) ALS…
Sanofi Announced Earlier: Dupixent Approved By European Commission As First And Only Targeted Medicine For Children As Young As Six Months Old With Severe Atopic Dermatitis
Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo
Why Enzo Biochem Stock Is Skyrocketing After Hours
Enzo Biochem Inc (NYSE: ENZ) shares are soaring in extended trading Thursday after the company agreed to sell its clinical lab to Laboratory Corporation Of America</
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
Dermavant Sciences, a Roivant Sciences Ltd. (NASDAQ:ROIV) company, announced results from ADORING 2 Phase 3 study evaluating VTAMA (tapinarof) cream, 1% in…
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE of rusfertide for polycythemia vera,…
Why Jounce Therapeutics Stock Is Moving Higher Today?
The Board of Directors of Jounce Therapeutics Inc (NASDAQ:JNCE) confirmed that Concentra Biosciences LLC made an unsolicited and non-binding proposal to acquire 100%…